Renovaro Inc. (NASDAQ: RENB) Aims To Revolutionize Cancer Detection And Treatment Using Multi-Cancer Detection Model With Nvidia AI Chips For Leadership In Early Detection

–News Direct–

By James Blacker, Benzinga

Despite the large numbers of people affected, cancer treatments have largely produced unsatisfactory results to curb the rise in cases. According to the American Cancer Society, more than 2 million new cancer cases are projected to be diagnosed in the United States in 2024, with over 600,000 cancer deaths expected to occur. Cancer is already the second-leading cause of death in the U.S. overall and the leading cause among people under 85, and analysis from Yale Medicine indicates that new cases of cancer are ticking upward.

Its clear the disease remains a formidable challenge, which is driving companies such as California-based biotechnology firm Renovaro Inc. (NASDAQ: RENB) to pioneer groundbreaking solutions to revolutionize diagnostics and offer more efficient treatment.

Renovaros Mission To Advance Cancer Care

Renovaro is on a mission to accelerate precision and offer personalized medicine for longevity. It leverages AI and biotechnology platforms to enable early diagnosis, better-targeted treatments and drug discovery.

The company comprises a biotech arm, RenovaroBio, which focuses on advanced cell-gene immunotherapy, and an AI arm, RenovaroCube, which is committed to the early detection of cancer, its recurrence and subsequent treatment.

Alliances With Industry Leaders

What makes Renovaros approach so unique is its AI platform for diagnosis, which was made possible thanks to a strategic alliance with Nvidia Corp. (NASDAQ: NVDA). In August 2023 Renovaro announced its alliance with Nvidias Inception program, which allows it to deploy next-generation AI running on Nvidias latest chips for greater accuracy in cancer detection.

Renovaro also announced in April that it plans to acquire 100% of Dutch health-tech firm Cyclomics, amending its initial agreement to acquire 75% of the company.

Once the acquisition is complete, Renovaro will be able to use Cyclomics 4th generation molecular technology, developed in partnership with Oxford Nanopore Technologies PLC (LON: ONT), to identify single cancer DNA molecules from a single vial of blood with nearly 100% accuracy.

Introducing Flamingo: A Game-Changer In Multi-Cancer Detection

Also in April this year, Renovaro unveiled Flamingo, a potentially groundbreaking multi-cancer detection model, according to the company. Flamingo leverages ultra-low pass whole genome sequencing of cell-free DNA (cfDNA), allowing early detection of cancers.

While traditional cancer detection methods can fail to identify cancer at an early stage when treatment is most effective Flamingo harnesses the power of AI to perform highly accurate analysis of minute amounts of cfDNA data to distinguish cancer from healthy samples.

Ultimately, this potentially allows cancer interventions to happen earlier and improves patient outcomes.

[Flamingo] will accelerate our efforts to realize a paradigm shift in cancer detection, shares RenovaroCube CTO Frank van Asch. With its introduction, we are one step closer to realizing our vision of a world where cancer is detected and treated swiftly, saving countless lives in the process.

Featured photo by National Cancer Institute on Unsplash.

Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

Contact Details

Benzinga

+1 877-440-9464

[email protected]

Company Website

http://www.benzinga.com

View source version on newsdirect.com: https://newsdirect.com/news/renovaro-inc-nasdaq-renb-aims-to-revolutionize-cancer-detection-and-treatment-using-multi-cancer-detection-model-with-nvidia-ai-chips-for-leadership-in-early-detection-437148551

Benzinga

comtex tracking

COMTEX_452007842/2655/2024-05-07T08:26:28

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Open Headline journalist was involved in the writing and production of this article.